MX2021012702A - Terminador de triple hélice para un empalme trans de arn eficiente. - Google Patents

Terminador de triple hélice para un empalme trans de arn eficiente.

Info

Publication number
MX2021012702A
MX2021012702A MX2021012702A MX2021012702A MX2021012702A MX 2021012702 A MX2021012702 A MX 2021012702A MX 2021012702 A MX2021012702 A MX 2021012702A MX 2021012702 A MX2021012702 A MX 2021012702A MX 2021012702 A MX2021012702 A MX 2021012702A
Authority
MX
Mexico
Prior art keywords
triple helix
terminator
trans splicing
efficient rna
splicing
Prior art date
Application number
MX2021012702A
Other languages
English (en)
Spanish (es)
Inventor
Jean Bennett
Krishna J Fisher
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2021012702A publication Critical patent/MX2021012702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2021012702A 2019-04-17 2020-04-17 Terminador de triple hélice para un empalme trans de arn eficiente. MX2021012702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835164P 2019-04-17 2019-04-17
PCT/US2020/028797 WO2020214973A1 (en) 2019-04-17 2020-04-17 Triple helix terminator for efficient rna trans-splicing

Publications (1)

Publication Number Publication Date
MX2021012702A true MX2021012702A (es) 2022-01-24

Family

ID=72837942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012702A MX2021012702A (es) 2019-04-17 2020-04-17 Terminador de triple hélice para un empalme trans de arn eficiente.

Country Status (11)

Country Link
US (1) US20220204989A1 (cg-RX-API-DMAC7.html)
EP (1) EP3956442A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022529065A (cg-RX-API-DMAC7.html)
KR (1) KR20220002910A (cg-RX-API-DMAC7.html)
CN (1) CN114040974B (cg-RX-API-DMAC7.html)
AU (1) AU2020260154B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133555A1 (cg-RX-API-DMAC7.html)
IL (1) IL287243A (cg-RX-API-DMAC7.html)
MX (1) MX2021012702A (cg-RX-API-DMAC7.html)
WO (1) WO2020214973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250150157A (ko) 2018-04-17 2025-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 트랜스-스플라이싱 분자
BR112021020539A2 (pt) * 2019-04-17 2022-01-04 Univ Pennsylvania Terminador de hélice tripla para trans-splicing de rna eficiente
EP4323391A4 (en) * 2021-04-15 2025-04-16 Tacit Therapeutics, Inc. HIGH-EFFICIENCY TRANS-SPLICING FOR TARGETED RNA SEQUENCE REPLACEMENT IN HUMAN CELLS
JP2024533163A (ja) 2021-09-03 2024-09-12 タシト・セラピューティクス・インコーポレーテッド スプライソソーム構成要素のリクルートを介したrna編集
WO2023205694A2 (en) * 2022-04-20 2023-10-26 Tacit Therapeutics, Inc. Stabilization of therapeutic trans-splicing rna molecules in human cells
EP4519436A4 (en) * 2022-05-03 2026-08-19 Tacit Therapeutics Inc LOCALIZATION OF NUCLEIC ACID MOLECULES TRANS-SPLICING TO AND WITHIN THE CELL NUCLEUS
KR20250011939A (ko) * 2022-05-13 2025-01-22 아시디엔 테라퓨틱스, 인크. Abca4 트랜스-스플라이싱 분자
EP4622662A1 (en) 2022-11-23 2025-10-01 Amber Bio Inc. Gene-modifying endonucleases
US12686869B1 (en) 2026-01-23 2026-07-21 Amber Bio Inc. Methods and compositions for trans-splicing utilizing trifunctional elements

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2151248A1 (en) * 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
CN104955951A (zh) * 2012-10-16 2015-09-30 麻省理工学院 稳定的非多腺苷酸化rna的产生
GB201219762D0 (en) * 2012-11-02 2012-12-19 Bauer Johann A RNA trans-splicing molecule (RTM) for use in the treatment of cancer
DK2986635T3 (en) * 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
AU2016355343C1 (en) * 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
US11795455B2 (en) * 2017-07-31 2023-10-24 Massachusetts Institute Of Technology RNA cleavage-induced transcript stabilizer and uses thereof
KR20250150157A (ko) * 2018-04-17 2025-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 트랜스-스플라이싱 분자
BR112021020539A2 (pt) * 2019-04-17 2022-01-04 Univ Pennsylvania Terminador de hélice tripla para trans-splicing de rna eficiente

Also Published As

Publication number Publication date
CA3133555A1 (en) 2020-10-22
CN114040974A (zh) 2022-02-11
WO2020214973A1 (en) 2020-10-22
EP3956442A1 (en) 2022-02-23
AU2020260154B2 (en) 2026-05-21
EP3956442A4 (en) 2023-01-25
US20220204989A1 (en) 2022-06-30
CN114040974B (zh) 2025-11-04
KR20220002910A (ko) 2022-01-07
JP2022529065A (ja) 2022-06-16
AU2020260154A1 (en) 2021-11-11
JP2025121988A (ja) 2025-08-20
IL287243A (en) 2021-12-01
BR112021020539A2 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
BR112021020539A2 (pt) Terminador de hélice tripla para trans-splicing de rna eficiente
MX2023014702A (es) Composiciones y metodos de arn circular.
MX2021010075A (es) Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
AR103446A1 (es) Método para modificar con precisión una planta a través de la expresión transitoria de genes
AR103162A1 (es) Anticuerpos anti-c5 y métodos para su uso
CO2021005040A2 (es) Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia
CL2021000874A1 (es) Procesamiento posterior de constructos de anticuerpos biespecíficos
MX2021015537A (es) Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
Naito et al. Bicuspid aortopathy–molecular involvement of microRNAs and MMP-TIMP
Ren et al. Tethering of Lsh at the Oct4 locus promotes gene repression associated with epigenetic changes
Mori et al. Glyoxysomal malate synthetase is specifically degraded in microbodies during greening of pumpkin cotyledons
Yamagata et al. 4D imaging reveals a shift in chromosome segregation dynamics during mouse pre-implantation development
Ehrenworth et al. Quantifying the efficiency of Saccharomyces cerevisiae translocation tags
CO2021003285A2 (es) Nucleasa pacas9
BR112017011182A8 (pt) Sequência oligonucleotídica para utilização na engenharia de via
UY40243A (es) Ácido nucleico aislado que codifica una proteína de fusión basada en fviii-bdd y en un péptido señal
BR0215982A (pt) Processo para a produção de etanol
Farsani et al. Consequences and Obstacles of Achieving the Virtue of Sincerity From the Point of View of Allameh Mohammad Taghi Jafari
Jost British Lyric Afterlives
FARIAS The materiality of Valdemar de Oliveira's textbooks and the school subject Natural History/Biology
Tang Consonant cluster variations in Hong Kong English: an attitudinal study
Mac Murchaidh Seanmóirí Muighe Nuadhad I-III (1906-08)
Taylor Emerging trends in global contact centres
UA48286S (uk) 1. комплект етикеток для пива «черкаси 1795»
Elmouwahidi et al. Acknowledgment to Reviewers of Electrochem in 2021